

## A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- has adenocarcinoma of the colon that has not been treated - plan is to do surgery for the cancer that is T4N0 or Stage III - tumor shows presence of either dMMR status or MSI-H - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete inclusion and exclusion criteria

#### Exclusion Criteria:

- received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of colon cancer - history of interstitial lung disease or pneumonitis - cirrhosis or current unstable liver or biliary disease - history of allogenic stem cell transplantation or organ transplantation - women who are pregnant, breastfeeding, or expecting to conceive children during the study

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Clinics and Surgery Center (CSC), colon cancer

### More Information

**Description:** The purpose of the study is to evaluate the safety and effectiveness of dostarlimab as compared with standard treatment with surgery in participants with untreated T4N0 or Stage III (resectable), dMMR/MSI-H colon cancer

**Study Contact:** Samantha Schommer - [schom217@umn.edu](mailto:schom217@umn.edu)

**Principal Investigator:** Emil Lou

**Phase:** PHASE3

**IRB**

**Number:** STUDY00021453

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.